Dr. Nezih Cereb, CEO & co-founder of HistoGenetics shares his reasons for adopting the PacBio DNA Sequencing platform for their operations and elaborates how the system’s unique ability to sequence full-length HLA amplicons irrespective of insert size and to provide fully phased HLA alleles will be used for HLA typing.
KIR haplotypes can be determined by physical and computational and statistical methods. Martin Maiers from National Bone Marrow Donor Program (NMDP) presents a summary of their work to determine KIR genomic content for use in clinical transplantation, outcomes of HLA sequencing of KIR region across a variety of methods and shares their data from recent experiments using PacBio single-molecule sequencing of fosmid libraries.
PacBio customers discuss their applications of PacBio SMRT Sequencing and long reads, including Lemuel Racacho (Children’s Hospital of Eastern Ontario Research Institute), Matthew Blow (JGI), Yuta Suzuki (U. of Tokyo), Daniel Geraghty (Fred Hutchinson Cancer Center), and Mike Schatz (CSHL)
Ulf Gyllensten speaks about advances in screening for HPV, his predictions for the widespread use of genome sequencing in the clinic, and applications using Single Molecule, Real-Time (SMRT) Sequencing for human genome studies.
Dan Geraghty explains that while there have been decades’ worth of studies associating the genetics of the major histocompatibility complex (MHC), and the highly polymorphic HLA class 1 and 2 genes, we still haven’t found the key mutations for a variety of different autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and others. Enormous amounts of linkage disequilibrium in these regions are one factor, as is getting information in phase, so larger stretches of sequence are needed. Recently Geraghty has begun using SMRT Technology with hopes of drilling down to the causal genetics.
Evan Eichler, Howard Hughes Medical Investigator from the University of Washington discusses his use of the PacBio system to study difficult-to-sequence regions of the human and chimp genomes. Eichler has identified a number of rapidly evolving hot spots in the human genome that are associated with disease. These regions are quite long and have extremely repetitive DNA sequence, making them difficult to elucidate with short-read sequencing and very expensive to interrogate with Sanger sequencing. Eichler’s goal is to fill in the missing regions of the human genome reference, many of which contain segmental duplications.
Dan Geraghty from the Fred Hutchinson Cancer Research Center says that PacBio sequencing “gives us access to genomic sequence data that’s not available by any other means.” He’s using it to understand the genetic basis of autoimmune diseases and has for the first time gotten answers to problems that have been challenging researchers for decades.
Dan Geraghty from the Fred Hutchinson Cancer Research Center presents his AGBT poster on a new PacBio-based solution to sequence extended genomic regions — in this case, KIR and MHC, two of the most variable regions of the human genome. He reports data revealing for the first time regions that may be associated with autoimmune diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis, and also shows that sequences were phased, complete, and highly accurate.
Bobby Sebra from the Icahn School of Medicine at Mount Sinai talks about how he uses PacBio sequencing for disease biology, pathogen surveillance, metagenomic sequencing, and more. With reads 70 kb or even longer, SMRT Sequencing lets him characterize tandem repeats and other structurally relevant elements that are inaccessible with short-read sequencing.
Ulf Gyllensten from Uppsala University describes his AGBT poster showing the use of SMRT Sequencing for HLA allele typing. He says long reads are essential for sequencing the HLA genes because they link exons in a single read and do not introduce bias, as short-read sequencers can. Looking at fusion transcripts from CML patients generated information that couldn’t be achieved with any other technology, he adds.
One of the popular questions on the Mendelspod program is how those doing sequencing decide between the quality of PacBio’s long reads and the cheaper short read technology, such as that of Illumina or Thermo Fisher. Steve Marsh, the Director of Bioinformatics at the Anthony Nolan Research Institute in London, provides the most clear and dramatic answer yet: use the PacBio system exclusively. Established in 1974 by the mother of a boy with a rare blood disease, the Anthony Nolan Institute is a world leader in blood crossmatching and donor/patient registries. Steve and his team at the Institute have dramatically…